Summary
In Coronavirus disease 2019 (COVID-19), the initial viral-replication phase is often followed by a hyperinflammatory reaction in the lungs and other organ systems that leads to acute respiratory distress syndrome (ARDS), the need for mechanical ventilation, and death despite maximal supportive care. As no antiviral treatments have yet proven effective, efforts to prevent progression to the severe stages of COVID-19 without inhibiting antiviral immune responses are desperately needed. We have previously demonstrated that a common, inexpensive, and well-tolerated class of drugs called alpha-1 adrenergic receptor (α1-AR) antagonists can prevent hyperinflammation (“cytokine storm”) and death in mice. We here present clinical data that supports the use of α1-AR antagonists in the prevention of severe complications of pneumonia, ARDS, and COVID-19.
Competing Interest Statement
Drs. Staedtke, Bai, Papadopoulos, Kinzler, Vogelstein, and Zhou are inventors on a patent application filed by Johns Hopkins University entitled “Preventing cytokine release syndrome”. Biomed Valley Discoveries has previously funded the work described in Staedke et al. and has licensed related patents from Johns Hopkins University. Drs. Papadopoulos, Kinzler, Vogelstein, and Zhou are entitled to a share of royalties received by the University from Biomed Valley Discoveries. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. Dr. Bettegowda reports personal fees from Depuy-Synthes and Bionaut Pharmaceuticals outside the submitted work.
Funding Statement
Dr. Konig was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award no. T32AR048522. This work was further supported by The Virginia and D.K. Ludwig Fund for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer Research, and the BKI Cancer Genetics and Genomics Research Program.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
NA
